Reviewer's report
Title:Clinicopathologic characteristics and treatment outcomes of hepatoid
adenocarcinoma of stomach, a rare but unique subtype of gastric cancer
Version: 1Date:11 January 2011
Reviewer: Takashi Kishimoto
Reviewer's report:
Major Compulsory Revisions
Authors have analyzed 26 cases of gastric hepatoid adenocarcinomas and
reported the results; (1) Clinicopathological data of 26 cases of gastric heptoid
adenocarcinomas. (2) Overall survival and disease-free survival in the cases with
curative resection. (3) Overall survival and progression free survival in the cases
with chemotherapy. Because gastric hepatoid adenocarcinoma is a rear but
highly malignant variant in gastric adenocarcinomas, statistical analysis has a
great value. But there are, I think, many ambiguous points that should be
improved in this manuscript.
1) Three cases of Stage IV are inoperable cases. Was the pathological diagnosis
made with biopsy specimens? It is generally difficult to make a final diagnosis of
hepatoid adenocarcinoma with biopsy specimens.
2) Histological characterizations (moderately and poorly differentiated type, and
Lauren’s intestinal, diffuse, and mixed type) are controversial. These
classifications may be inadequate for hepatoid adenocarcinomas.
3) There are 23 cases with surgical resection. All cases should be reviewed for
vascular and lymphatic invasion for discussing the relation between
endovascular or endolymphatic tumor emboli and the recurrence of tumors.
4) Indication for chemotherapy should be described. Don’t you apply
chemotherapy for the cured cases with advanced tumor? (I think “disease-free”
or “without recurrence” would be better that “cure”)
5) Explanation of Table 1 in Results (2) are somewhat complicated and
unintelligible.
6) Numerical values of serum AFP, endovascular tumor emboli, endolymphatic
tumor emboli, and liver metastasis may be different between text and Tables.
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Needs some language corrections before being
published
Statistical review: Yes, but I do not feel adequately qualified to assess the
statistics.
Declaration of competing interests:
I declare that I have no competing interests.
Reviewer's report
Title:Clinicopathologic characteristics and treatment outcomes of hepatoid
adenocarcinoma of stomach, a rare but unique subtype of gastric cancer
Version: 1Date:11 January 2011
Reviewer: Takashi Kishimoto
Reviewer's report:
Major Compulsory Revisions
Authors have analyzed 26 cases of gastric hepatoid adenocarcinomas and
reported the results; (1) Clinicopathological data of 26 cases of gastric heptoid
adenocarcinomas. (2) Overall survival and disease-free survival in the cases with
curative resection. (3) Overall survival and progression free survival in the cases
with chemotherapy. Because gastric hepatoid adenocarcinoma is a rear but
highly malignant variant in gastric adenocarcinomas, statistical analysis has a
great value. But there are, I think, many ambiguous points that should be
improved in this manuscript.
1) Three cases of Stage IV are inoperable cases. Was the pathological diagnosis
made with biopsy specimens? It is generally difficult to make a final diagnosis of
hepatoid adenocarcinoma with biopsy specimens.
2) Histological characterizations (moderately and poorly differentiated type, and
Lauren’s intestinal, diffuse, and mixed type) are controversial. These
classifications may be inadequate for hepatoid adenocarcinomas.
3) There are 23 cases with surgical resection. All cases should be reviewed for
vascular and lymphatic invasion for discussing the relation between
endovascular or endolymphatic tumor emboli and the recurrence of tumors.
4) Indication for chemotherapy should be described. Don’t you apply
chemotherapy for the cured cases with advanced tumor? (I think “disease-free”
or “without recurrence” would be better that “cure”)
5) Explanation of Table 1 in Results (2) are somewhat complicated and
unintelligible.
6) Numerical values of serum AFP, endovascular tumor emboli, endolymphatic
tumor emboli, and liver metastasis may be different between text and Tables.
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Needs some language corrections before being
published
Statistical review: Yes, but I do not feel adequately qualified to assess the
statistics.
Declaration of competing interests:
I declare that I have no competing interests.
Please review this paper.
user
Reviewer's report
Title:Clinicopathologic characteristics and treatment outcomes of hepatoid
adenocarcinoma of stomach, a rare but unique subtype of gastric cancer
Version: 1Date:11 January 2011
Reviewer: Takashi Kishimoto
Reviewer's report:
Major Compulsory Revisions
Authors have analyzed 26 cases of gastric hepatoid adenocarcinomas and
reported the results; (1) Clinicopathological data of 26 cases of gastric heptoid
adenocarcinomas. (2) Overall survival and disease-free survival in the cases with
curative resection. (3) Overall survival and progression free survival in the cases
with chemotherapy. Because gastric hepatoid adenocarcinoma is a rear but
highly malignant variant in gastric adenocarcinomas, statistical analysis has a
great value. But there are, I think, many ambiguous points that should be
improved in this manuscript.
1) Three cases of Stage IV are inoperable cases. Was the pathological diagnosis
made with biopsy specimens? It is generally difficult to make a final diagnosis of
hepatoid adenocarcinoma with biopsy specimens.
2) Histological characterizations (moderately and poorly differentiated type, and
Lauren’s intestinal, diffuse, and mixed type) are controversial. These
classifications may be inadequate for hepatoid adenocarcinomas.
3) There are 23 cases with surgical resection. All cases should be reviewed for
vascular and lymphatic invasion for discussing the relation between
endovascular or endolymphatic tumor emboli and the recurrence of tumors.
4) Indication for chemotherapy should be described. Don’t you apply
chemotherapy for the cured cases with advanced tumor? (I think “disease-free”
or “without recurrence” would be better that “cure”)
5) Explanation of Table 1 in Results (2) are somewhat complicated and
unintelligible.
6) Numerical values of serum AFP, endovascular tumor emboli, endolymphatic
tumor emboli, and liver metastasis may be different between text and Tables.
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Needs some language corrections before being
published
Statistical review: Yes, but I do not feel adequately qualified to assess the
statistics.
Declaration of competing interests:
I declare that I have no competing interests.
assistant